Sarepta Therapeutics (SRPT) option implied volatility elevated
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Evercore on Sarepta (SRPT) Post Stat News Article: 'probably sets up for the adcomm briefing documents and tone to be somewhat more negative'
April 13, 2023 10:39 AM EDTEvercore ISI analyst Gavin Clark-Gartner reiterated an Outperform rating and $149.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).
The analyst comments "The STAT article from this morning (HERE) is a must-read. To briefly summarize: the market had thought SRPTs... More
